Notify me when Sio Capital Management, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 65 | $603,158,458 | +$312,473,530 | -$179,518,728 | +$132,954,802 | CELC, CI, SNY, MMS, ZBH | 13F-HR | 17 Feb 2026, 10:00 |
| Q3 2025 | 51 | $395,154,620 | +$190,608,917 | -$104,758,547 | +$85,850,370 | MMS, CELC, SNY, DNTH, ALKS | 13F-HR | 13 Nov 2025, 15:43 |
| Q2 2025 | 49 | $249,178,328 | +$79,052,287 | -$157,199,248 | -$78,146,961 | MMS, IRON, GMED, CNC, MRK | 13F-HR | 13 Aug 2025, 14:00 |
| Q1 2025 | 53 | $330,203,349 | +$136,078,305 | -$105,552,500 | +$30,525,805 | ICLR, MMS, MRK, ZBH, NBIX | 13F-HR | 15 May 2025, 14:00 |
| Q4 2024 | 51 | $355,411,105 | +$233,354,827 | -$84,170,515 | +$149,184,312 | ICLR, MMS, CI, LH, SNY | 13F-HR | 14 Feb 2025, 11:00 |
| Q3 2024 | 38 | $223,191,855 | +$71,629,459 | -$136,010,694 | -$64,381,235 | LH, TEVA, MMS, ZBH, VXRT | 13F-HR | 14 Nov 2024, 14:00 |
| Q2 2024 | 46 | $265,193,751 | +$170,011,885 | -$169,578,936 | +$432,949 | LH, TFX, ZBH, SNN, OGN | 13F-HR | 14 Aug 2024, 14:00 |
| Q1 2024 | 48 | $287,146,088 | +$121,060,334 | -$249,919,243 | -$128,858,909 | LH, CI, GMED, MDGL, GSK | 13F-HR | 15 May 2024, 13:00 |
| Q4 2023 | 39 | $388,411,076 | +$166,860,093 | -$141,527,915 | +$25,332,178 | MRTX, GRCL, LH, CI, GMED | 13F-HR | 13 Feb 2024, 14:00 |
| Q3 2023 | 52 | $323,082,299 | +$151,233,765 | -$74,366,912 | +$76,866,853 | LH, GMED, GSK, UTHR, CI | 13F-HR | 14 Nov 2023, 14:00 |
| Q2 2023 | 41 | $282,856,202 | +$156,404,803 | -$83,024,744 | +$73,380,059 | GEHC, LH, CI, BCYC, UTHR | 13F-HR | 14 Aug 2023, 15:36 |
| Q1 2023 | 44 | $202,279,540 | +$104,500,425 | -$73,962,588 | +$30,537,837 | CNC, CI, BCYC, COR, UTHR | 13F-HR | 12 May 2023, 16:00 |
| Q4 2022 | 42 | $187,593,315 | +$55,751,535 | -$118,750,188 | -$62,998,653 | MSAC, BCYC, CI, OGN, UTHR | 13F-HR | 13 Feb 2023, 16:00 |
| Q3 2022 | 43 | $233,665,000 | +$64,658,809 | -$79,324,256 | -$14,665,447 | COR, GSK, MSAC, BCYC, OGN | 13F-HR | 14 Nov 2022, 12:49 |
| Q2 2022 | 59 | $253,788,000 | +$134,029,905 | -$110,982,166 | +$23,047,739 | COR, MSAC, OGN, CI, INGN | 13F-HR | 15 Aug 2022, 13:34 |
| Q1 2022 | 61 | $247,890,000 | +$70,271,864 | -$133,695,360 | -$63,423,496 | MSAC, CI, MRK, SNY, LH | 13F-HR | 16 May 2022, 14:00 |
| Q4 2021 | 67 | $328,429,000 | +$129,983,848 | -$95,007,770 | +$34,976,078 | CI, MSAC, CRIS, MRK, CAH | 13F-HR | 14 Feb 2022, 14:03 |
| Q3 2021 | 59 | $310,200,000 | +$68,930,843 | -$101,124,699 | -$32,193,856 | CI, CRIS, GLD, SOLY, UHS | 13F-HR | 15 Nov 2021, 15:00 |
| Q2 2021 | 72 | $368,656,000 | +$73,255,706 | -$165,782,338 | -$92,526,632 | CRIS, CI, SOLY, GLD, AVAH | 13F-HR | 16 Aug 2021, 16:00 |
| Q1 2021 | 85 | $478,271,000 | +$143,679,210 | -$157,264,385 | -$13,585,175 | CRIS, CI, CAH, GLD, SOLY | 13F-HR | 14 May 2021, 16:00 |
| Q4 2020 | 86 | $456,688,000 | +$133,562,383 | -$217,123,453 | -$83,561,070 | CRIS, GLD, SPRB, CHRS, ALBO | 13F-HR | 16 Feb 2021, 13:03 |
| Q3 2020 | 85 | $450,730,000 | +$222,671,423 | -$94,412,830 | +$128,258,593 | GLD, CHRS, MCK, JNJ, HRC | 13F-HR | 16 Nov 2020, 14:00 |
| Q2 2020 | 72 | $323,481,000 | +$142,920,961 | -$158,449,974 | -$15,529,013 | CHRS, GLD, MCK, TEVA, GWPH | 13F-HR | 14 Aug 2020, 14:00 |
| Q1 2020 | 66 | $280,125,000 | +$156,276,589 | -$181,496,077 | -$25,219,488 | AMGN, MCK, CHRS, GWPH, BIIB | 13F-HR | 15 May 2020, 15:40 |
| Q4 2019 | 60 | $328,763,000 | +$129,034,952 | -$108,085,959 | +$20,948,993 | GWPH, AGN, CHRS, MDT, HCA | 13F-HR | 14 Feb 2020, 16:00 |
| Q3 2019 | 52 | $281,213,000 | +$119,060,899 | -$140,666,798 | -$21,605,899 | GWPH, JNJ, AGN, HCA, WCG | 13F-HR | 14 Nov 2019, 16:00 |
| Q2 2019 | 60 | $324,984,000 | +$145,380,778 | -$139,945,906 | +$5,434,872 | GWPH, HCA, WCG, GSK, MRTX | 13F-HR | 14 Aug 2019, 16:00 |
| Q1 2019 | 60 | $326,604,000 | +$155,689,366 | -$111,880,399 | +$43,808,967 | CVS, BIIB, GILD, HCA, MDT | 13F-HR | 15 May 2019, 16:00 |
| Q4 2018 | 66 | $259,399,000 | +$157,017,002 | -$94,533,804 | +$62,483,198 | MDT, SNY, ALNY, COR, CI | 13F-HR | 14 Feb 2019, 16:00 |
| Q3 2018 | 51 | $232,790,000 | +$113,650,422 | -$55,291,035 | +$58,359,387 | GSK, CI, KURA, AET, SNY | 13F-HR | 14 Nov 2018, 16:00 |
| Q2 2018 | 40 | $161,395,000 | +$82,817,302 | -$79,445,553 | +$3,371,749 | KURA, ELV, HCA, MEIP, ICLR | 13F-HR | 14 Aug 2018, 16:02 |
| Q1 2018 | 28 | $160,147,000 | +$103,987,756 | -$53,120,463 | +$50,867,293 | CBIO, SNY, KURA, ELV, BIIB | 13F-HR | 15 May 2018, 16:00 |
| Q4 2017 | 33 | $106,099,000 | +$48,151,396 | -$73,951,849 | -$25,800,453 | GSK, AET, ELV, QTNT, KURA | 13F-HR | 14 Feb 2018, 16:01 |
| Q3 2017 | 43 | $124,894,000 | +$59,440,525 | -$67,711,891 | -$8,271,366 | QTNT, ADMP, AET, AXGT, GSK | 13F-HR | 14 Nov 2017, 16:00 |
| Q2 2017 | 40 | $131,821,000 | +$41,165,771 | -$52,900,623 | -$11,734,852 | QTNT, SNY, AET, PHG, PBYI | 13F-HR | 14 Aug 2017, 16:00 |
| Q1 2017 | 36 | $129,908,000 | +$61,176,695 | -$39,477,354 | +$21,699,341 | QTNT, SNY, GSK, PHG, BIIB | 13F-HR | 15 May 2017, 16:00 |
| Q4 2016 | 28 | $95,926,000 | +$44,676,889 | -$42,053,573 | +$2,623,316 | QTNT, GSK, PHG, HRC, TRHC | 13F-HR | 14 Feb 2017, 16:00 |
| Q3 2016 | 26 | $103,555,000 | +$30,470,151 | -$67,282,340 | -$36,812,189 | QTNT, PHG, CAH, SNY, TRHC | 13F-HR | 15 Nov 2016, 09:38 |
| Q2 2016 | 32 | $132,274,000 | +$45,615,720 | -$132,909,125 | -$87,293,405 | QTNT, BIIB, CAH, PHG, SNY | 13F-HR | 15 Aug 2016, 16:31 |
| Q1 2016 | 38 | $228,164,000 | +$136,374,505 | -$104,495,352 | +$31,879,153 | QTNT, NEOS, MCK, AMGN, ANTH | 13F-HR | 16 May 2016, 16:01 |
| Q4 2015 | 41 | $223,905,000 | +$127,796,205 | -$54,663,734 | +$73,132,471 | QTNT, DYAX, SNY, NEOS, MCK | 13F-HR | 16 Feb 2016, 16:01 |
| Q3 2015 | 35 | $144,041,000 | +$74,464,615 | -$35,296,684 | +$39,167,931 | QTNT, NEOS, JNJ, MDT, CAH | 13F-HR | 13 Nov 2015, 16:15 |
| Q2 2015 | 31 | $123,934,000 | +$73,667,900 | -$38,941,614 | +$34,726,286 | QTNT, GSK, RXDX, FLML, PFNX | 13F-HR | 14 Aug 2015, 16:06 |
| Q1 2015 | 23 | $89,298,000 | +$37,369,755 | -$79,155,199 | -$41,785,444 | QTNT, PFNX, MRK, UTHR, CAH | 13F-HR | 15 May 2015, 16:01 |
| Q4 2014 | 30 | $127,116,000 | $0 | $0 | $0 | QTNT, SNY, GSK, F113PS, ADMP | 13F-HR | 17 Feb 2015, 16:14 |